Coverage Policy Manual
Policy #: 2022013
Category: Medicine
Initiated: March 2022
Last Review: March 2024
  Medical Technology Assessment, Non-Covered Services
Description:
The services listed in this policy do not meet Arkansas Blue Cross Blue Shield primary coverage criteria. For member benefit certificates (contracts) without primary coverage criteria, these services are considered investigational. Definitions of Primary Coverage Criteria can be found in the member’s benefit certificate.
Policy/
Coverage:
Effective January 2024
 
Does Not Meet Primary Coverage Criteria Or Is Investigational For Contracts Without Primary Coverage Criteria
 
Category III CPT Codes
 
ALL category III CPT Codes are non-covered unless the code is explicitly addressed as a covered service in an Arkansas Blue Cross Medical Coverage Policy. If there is no associated policy, the code is non-covered.
 
Current Procedural Terminology (CPT), the official code book with rules and guidelines from the American Medical Association’s CPT editorial panel, includes a section of Category III CPT codes. Category III codes are temporary codes created to identify emerging technology services and procedures.
 
Unlike unlisted or deleted codes, the Category III codes allow data collection for specific emerging technology services. If a Category III code is available, providers must use that code instead of an unlisted or deleted Category I code. The services or procedures represented by Category III codes may not have FDA approval, may not be performed by many health care professionals across the country, and the service or procedure may not have proven clinical efficacy.
 
Claims filed for services using Category III codes will be denied unless the code is addressed as a covered service in an Arkansas Blue Cross Medical Coverage Policy.
 
Proprietary Laboratory Analysis (PLA) Codes
 
All PLA codes are non-covered unless the code is explicitly addressed as a covered service in Arkansas Blue Cross Medical Coverage Policy. If there is no associated policy, the code is non-covered.
 
Current Procedural Terminology (CPT), the official code book with rules and guidelines from the American Medical Association’s CPT editorial panel, includes a section of Proprietary Laboratory Analyses (PLA) codes which are a part of the overall code sets developed and released by the American Medical Association - Current Procedural Terminology (AMA-CPT) Editorial Panel. PLA codes describe proprietary analyses and may be provided by “one, sole source” laboratory or may be licensed to multiple labs that may provide the analysis. They are meant to represent specific laboratory tests developed by a proprietary lab.
 
The PLA code set includes:
• Advanced Diagnostic Laboratory Tests (ADLTs)
• Clinical Diagnostic Laboratory Tests (CDLTs)
• Multianalyte Assays with Algorithmic Analyses (MAAA)
• Genomic Sequencing Procedures.
 
When the PLA code is released, it generally is not released with information clearly demonstrating that clinical validity or clinical utility have been proven OR, that a definitive positive incremental impact on clinical outcomes has been established. PLA codes are updated quarterly.
 
Non-covered CPT and HCPCS Codes
 
The CPT and HCPCS codes below do not meet member benefit certificate primary coverage criteria that there be scientific evidence of effectiveness in improving health outcomes or are investigational for contracts without primary coverage criteria.
Rationale:
 
CPT/HCPCS:
0005UOncology (prostate) gene expression profile by real time RT PCR of 3 genes (ERG, PCA3, and SPDEF), urine, algorithm reported as risk score
0042TCerebral perfusion analysis using computed tomography with contrast administration, including post processing of parametric maps with determination of cerebral blood flow, cerebral blood volume, and mean transit time
0054TComputer assisted musculoskeletal surgical navigational orthopedic procedure, with image guidance based on fluoroscopic images (List separately in addition to code for primary procedure)
0055TComputer assisted musculoskeletal surgical navigational orthopedic procedure, with image guidance based on CT/MRI images (List separately in addition to code for primary procedure)
0063UNeurology (autism), 32 amines by LC MS/MS, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder
0075TTranscatheter placement of extracranial vertebral artery stent(s), including radiologic supervision and interpretation, open or percutaneous; initial vessel
0076TTranscatheter placement of extracranial vertebral artery stent(s), including radiologic supervision and interpretation, open or percutaneous; each additional vessel (List separately in addition to code for primary procedure)
0095TRemoval of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, cervical (List separately in addition to code for primary procedure)
0098TRevision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, cervical (List separately in addition to code for primary procedure)
0101TExtracorporeal shock wave involving musculoskeletal system, not otherwise specified
0102TExtracorporeal shock wave, performed by a physician, requiring anesthesia other than local, and involving the lateral humeral epicondyle
0106TQuantitative sensory testing (QST), testing and interpretation per extremity; using touch pressure stimuli to assess large diameter sensation
0107TQuantitative sensory testing (QST), testing and interpretation per extremity; using vibration stimuli to assess large diameter fiber sensation
0108TQuantitative sensory testing (QST), testing and interpretation per extremity; using cooling stimuli to assess small nerve fiber sensation and hyperalgesia
0109TQuantitative sensory testing (QST), testing and interpretation per extremity; using heat pain stimuli to assess small nerve fiber sensation and hyperalgesia
0110TQuantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensation
0163TTotal disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression), each additional interspace, lumbar (List separately in addition to code for primary procedure)
0164TRemoval of total disc arthroplasty, (artificial disc), anterior approach, each additional interspace, lumbar (List separately in addition to code for primary procedure)
0165TRevision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, lumbar (List separately in addition to code for primary procedure)
0170UNeurology (autism spectrum disorder [ASD]), RNA, next generation sequencing, saliva, algorithmic analysis, and results reported as predictive probability of ASD diagnosis
0174TComputer aided detection (CAD) (computer algorithm analysis of digital image data for lesion detection) with further physician review for interpretation and report, with or without digitization of film radiographic images, chest radiograph(s), performed concurrent with primary interpretation (List separately in addition to code for primary procedure)
0175TComputer aided detection (CAD) (computer algorithm analysis of digital image data for lesion detection) with further physician review for interpretation and report, with or without digitization of film radiographic images, chest radiograph(s), performed remote from primary interpretation
0198TMeasurement of ocular blood flow by repetitive intraocular pressure sampling, with interpretation and report
0200TPercutaneous sacral augmentation (sacroplasty), unilateral injection(s), including the use of a balloon or mechanical device, when used, 1 or more needles, includes imaging guidance and bone biopsy, when performed
0201TPercutaneous sacral augmentation (sacroplasty), bilateral injections, including the use of a balloon or mechanical device, when used, 2 or more needles, includes imaging guidance and bone biopsy, when performed
0202TPosterior vertebral joint(s) arthroplasty (eg, facet joint[s] replacement), including facetectomy, laminectomy, foraminotomy, and vertebral column fixation, injection of bone cement, when performed, including fluoroscopy, single level, lumbar spine
0207TEvacuation of meibomian glands, automated, using heat and intermittent pressure, unilateral
0208TPure tone audiometry (threshold), automated; air only
0209TPure tone audiometry (threshold), automated; air and bone
0210TSpeech audiometry threshold, automated;
0211TSpeech audiometry threshold, automated; with speech recognition
0212TComprehensive audiometry threshold evaluation and speech recognition (0209T, 0211T combined), automated
0213TInjection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; single level
0214TInjection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; second level (List separately in addition to code for primary procedure)
0215TInjection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; third and any additional level(s) (List separately in addition to code for primary procedure)
0216TInjection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; single level
0217TInjection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; second level (List separately in addition to code for primary procedure)
0218TInjection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; third and any additional level(s) (List separately in addition to code for primary procedure)
0219TPlacement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; cervical
0220TPlacement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; thoracic
0221TPlacement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; lumbar
0222TPlacement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; each additional vertebral segment (List separately in addition to code for primary procedure)
0232TInjection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed
0234TTransluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; renal artery
0235TTransluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; visceral artery (except renal), each vessel
0236TTransluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; abdominal aorta
0237TTransluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; brachiocephalic trunk and branches, each vessel
0238TTransluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; iliac artery, each vessel
0263TIntramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure including unilateral or bilateral bone marrow harvest
0263UNeurology (autism spectrum disorder [ASD]), quantitative measurements of 16 central carbon Metabolites (ie, aketoglutarate, alanine, lactate, phenylalanine, pyruvate, succinate, carnitine, citrate, fumarate, hypoxanthine, inosine, malate, S-sulfocysteine, taurine, urate, and xanthine), liquid chromatography tandem mass spectrometry (LC-MS/MS), plasma, algorithmic analysis with result reported as negative or positive (with metabolic subtypes of ASD)
0264TIntramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure excluding bone marrow harvest
0265TIntramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; unilateral or bilateral bone marrow harvest only for intramuscular autologous bone marrow cell therapy
0266TImplantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra operative interrogation, programming, and repositioning, when performed)
0267TImplantation or replacement of carotid sinus baroreflex activation device; lead only, unilateral (includes intra operative interrogation, programming, and repositioning, when performed)
0268TImplantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra operative interrogation, programming, and repositioning, when performed)
0269TRevision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra operative interrogation, programming, and repositioning, when performed)
0269UHematology (autosomal dominant congenital thrombocytopenia), genomic sequence analysis of 22 genes, blood, buccal swab, or amniotic fluid
0270TRevision or removal of carotid sinus baroreflex activation device; lead only, unilateral (includes intra operative interrogation, programming, and repositioning, when performed)
0271TRevision or removal of carotid sinus baroreflex activation device; pulse generator only (includes intra operative interrogation, programming, and repositioning, when performed)
0271UHematology (congenital neutropenia), genomic sequence analysis of 24 genes, blood, buccal swab, or amniotic fluid
0272TInterrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day);
0272UHematology (genetic bleeding disorders), genomic sequence analysis of 60 genes and duplication/deletion of PLAU, blood, buccal swab, or amniotic fluid, comprehensive
0273TInterrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day); with programming
0274TPercutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), single or multiple levels, unilateral or bilateral; cervical or thoracic
0274UHematology (genetic platelet disorders), genomic sequence analysis of 62 genes and duplication/deletion of PLAU, blood, buccal swab, or amniotic fluid
0275TPercutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), single or multiple levels, unilateral or bilateral; lumbar
0277UHematology (genetic platelet function disorder), genomic sequence analysis of 40 genes and duplication/deletion of PLAU, blood, buccal swab, or amniotic fluid
0278TTranscutaneous electrical modulation pain reprocessing (eg, scrambler therapy), each treatment session (includes placement of electrodes)
0278UHematology (genetic thrombosis), genomic sequence analysis of 14 genes, blood, buccal swab, or amniotic fluid
0303UHematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; hypoxic
0304UHematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; normoxic
0305UHematology, red blood cell (RBC) functionality and deformity as a function of shear stress, whole blood, reported as a maximum elongation index
0308TInsertion of ocular telescope prosthesis including removal of crystalline lens or intraocular lens prosthesis
0308UCardiology (coronary artery disease [CAD]), analysis of 3 proteins (high sensitivity [hs] troponin, diponectin, and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for obstructive CAD
0309UCardiology (cardiovascular disease), analysis of 4 proteins (NT-proBNP, osteopontin, tissue inhibitor of metalloproteinase-1 [TIMP-1], and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for major adverse cardiac event
0310UPediatrics (vasculitis, Kawasaki disease [KD]), analysis of 3 biomarkers (NTproBNP, C-reactive protein, and T-uptake), plasma, algorithm reported as a risk score for KD
0311UInfectious disease (bacterial), quantitative antimicrobial susceptibility reported as phenotypic minimum inhibitory concentration (MIC)–based antimicrobial susceptibility for each organisms identified
0312TVagus nerve blocking therapy (morbid obesity); laparoscopic implantation of neurostimulator electrode array, anterior and posterior vagal trunks adjacent to esophagogastric junction (EGJ), with implantation of pulse generator, includes programming
0313TVagus nerve blocking therapy (morbid obesity); laparoscopic revision or replacement of vagal trunk neurostimulator electrode array, including connection to existing pulse generator
0314TVagus nerve blocking therapy (morbid obesity); laparoscopic removal of vagal trunk neurostimulator electrode array and pulse generator
0315TVagus nerve blocking therapy (morbid obesity); removal of pulse generator
0316TVagus nerve blocking therapy (morbid obesity); replacement of pulse generator
0316UBorrelia burgdorferi (Lyme disease), OspA protein evaluation, urine
0317TVagus nerve blocking therapy (morbid obesity); neurostimulator pulse generator electronic analysis, includes reprogramming when performed
0322UNeurology (autism spectrum disorder [ASD]), quantitative measurements of 14 acyl carnitines and microbiome-derived metabolites, liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma, results reported as negative or positive for risk of metabolic subtypes associated with ASD
0324UOncology (ovarian), spheroid cell culture, four drug panel (carboplatin, doxorubicin, gemcitabine, paclitaxel), tumor chemotherapy response prediction for each drug
0325UOncology (ovarian), spheroid cell culture, poly (ADP-ribose) polymerase (PARP) inhibitors (niraparib, olaparib, rucaparib, velparib), tumor response prediction for each drug
0329TMonitoring of intraocular pressure for 24 hours or longer, unilateral or bilateral, with interpretation and report
0330TTear film imaging, unilateral or bilateral, with interpretation and report
0331TMyocardial sympathetic innervation imaging, planar qualitative and quantitative assessment;
0332TMyocardial sympathetic innervation imaging, planar qualitative and quantitative assessment; with tomographic SPECT
0332UOncology (pan-tumor), genetic profiling of 8 DNA-regulatory (epigenetic) markers by quantitative polymerase chain reaction (qPCR), whole blood, reported as a high or low probability of responding to immune checkpoint–inhibitor therapy
0333TVisual evoked potential, screening of visual acuity, automated, with report
0333UOncology (liver), surveillance for hepatocellular carcinoma (HCC) in highrisk patients, analysis of methylation patterns on circulating cell-free DNA (cfDNA) plus measurement of serum of AFP/AFP-L3 and oncoprotein des-gammacarboxy-prothrombin (DCP), algorithm reported as normal or abnormal result
0335TInsertion of sinus tarsi implant
0338TTranscatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; unilateral
0339TTranscatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; bilateral
0341UFetal aneuploidy DNA sequencing comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and segmental aneuploid
0342TTherapeutic apheresis with selective HDL delipidation and plasma reinfusion
0342UOncology (pancreatic cancer), multiplex immunoassay of C5, C4, cystatin C, factor B, osteoprotegerin (OPG), gelsolin, IGFBP3, CA125 and multiplex electrochemiluminescent immunoassay (ECLIA) for CA19-9, serum, diagnostic algorithm reported qualitatively as positive, negative, or borderline
0345TTranscatheter mitral valve repair percutaneous approach via the coronary sinus
0346UBeta amyloid, Aß40 and Aß42 by liquid chromatography with tandem mass spectrometry (LC-MS/MS), ratio, plasma
0347TPlacement of interstitial device(s) in bone for radiostereometric analysis (RSA)
0348TRadiologic examination, radiostereometric analysis (RSA); spine, (includes cervical, thoracic and lumbosacral, when performed)
0349TRadiologic examination, radiostereometric analysis (RSA); upper extremity(ies), (includes shoulder, elbow, and wrist, when performed)
0350TRadiologic examination, radiostereometric analysis (RSA); lower extremity(ies), (includes hip, proximal femur, knee, and ankle, when performed)
0351TOptical coherence tomography of breast or axillary lymph node, excised tissue, each specimen; real time intraoperative
0351UInfectious disease (bacterial or viral), biochemical assays, tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein-10 (IP10), and C-reactive protein, serum, or venous whole blood, algorithm reported as likelihood of bacterial infection.
0352TOptical coherence tomography of breast or axillary lymph node, excised tissue, each specimen; interpretation and report, real time or referred
0353TOptical coherence tomography of breast, surgical cavity; real time intraoperative
0354TOptical coherence tomography of breast, surgical cavity; interpretation and report, real time or referred
0355UAPOL1 (apolipoprotein L1) (eg, chronic kidney disease), risk variants (G1, G2)
0356UOncology (oropharyngeal or anal), evaluation of 17 DNA biomarkers using droplet digital PCR (ddPCR), cell-free DNA, algorithm reported as a prognostic risk score for cancer recurrence
0357UOncology (melanoma), artificial intelligence (AI)-enabled quantitative mass spectrometry analysis of 142 unique pairs of glycopeptide and product fragments, plasma, prognostic, and predictive algorithm reported as likely, unlikely, or uncertain benefit f
0358TBioelectrical impedance analysis whole body composition assessment, with interpretation and report
0359UOncology (prostate cancer), analysis of all prostate-specific antigen (PSA) structural isoforms by phase separation and immunoassay, plasma, algorithm reports risk of cancer
0360UOncology (lung), enzyme-linked immunosorbent assay (ELISA) of 7 autoantibodies (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, MAGE A4, and HuD), plasma, algorithm reported as a categorical result for risk of malignancy
0361UNeurofilament light chain, digital immunoassay, plasma, quantitative
0362UOncology (papillary thyroid cancer), gene-expression profiling via targeted hybrid capture–enrichment RNA sequencing of 82 content genes and 10 housekeeping genes, fine needle aspirate or formalin-fixed paraffinembedded (FFPE) tissue, algorithm reported as one of three molecular subtype
0363UOncology (urothelial), mRNA, geneexpression profiling by real-time quantitative PCR of 5 genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm incorporates age, sex, smoking history, and macrohematuria frequency, reported as a ri
0365UOncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, algorithm reported as a probability of bladder cancer
0366UOncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, algorithm reported as a probability of recurrent bladder cancer
0367UOncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, diagnostic algorithm reported as a risk score for probability of rapid recurrence of recurrent or persistent cancer following transurethral resection
0375UOncology (ovarian), biochemical assays of 7 proteins (follicle stimulating hormone, human epididymis protein 4, apolipoprotein A-1, transferrin, beta-2 macroglobulin, prealbumin [ie, transthyretin], and cancer antigen 125), algorithm reported as ovarian cancer risk score
0378TVisual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified health care professional
0378URFC1 (replication factor C subunit 1), repeat expansion variant analysis by traditional and repeat-primed PCR, blood, saliva, or buccal swab
0379TVisual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; technical support and patient instructions, surveillance, analysis, and transmission of daily and emergent data reports as prescribed by a physician or other qualified health care professional
0381UMaple syrup urine disease monitoring by patient-collected blood card sample, quantitative measurement of alloisoleucine, leucine, isoleucine, and valine, liquid chromatography with tandem mass spectrometry (LC-MS/MS)
0382UHyperphenylalaninemia monitoring by patient-collected blood card sample, quantitative measurement of phenylalanine and tyrosine, liquid chromatography with tandem mass spectrometry (LC-MS/MS)
0383UTyrosinemia type I monitoring by patient-collected blood card sample, quantitative measurement of tyrosine, phenylalanine, methionine, succinylacetone, nitisinone, liquid chromatography with tandem mass spectrometry (LC-MS/MS)
0385UNephrology (chronic kidney disease), apolipoprotein A4 (ApoA4), CD5 antigen-like (CD5L), and insulin-like growth factor binding protein 3 (IGFBP3) by enzyme-linked immunoassay (ELISA), plasma, algorithm combining results with HDL, estimated glomerular filtration rate (GFR) and clinical data reported as a risk score for developing diabetic kidney disease
0389UPediatric febrile illness (Kawasaki disease KD), interferon alphainducible protein 27 (IFI27) and mast cell-expressed membrane protein 1 (MCEMP1), RNA, using quantitative reverse transcription polymerase chain reaction (RTqPCR), blood, reported as a risk score for KD
0393UNeurology (eg, Parkinson disease, dementia with Lewy bodies), cerebrospinal fluid (CSF), detection of misfolded a-synuclein protein by seed amplification asssay, qualitative
0394THigh dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed
0395THigh dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed
0397TEndoscopic retrograde cholangiopancreatography (ERCP), with optical endomicroscopy (List separately in addition to code for primary procedure)
0399UNeurology (cerebral folate deficiency), serum, detection of anti-human folate receptor IgG-binding antibody and blocking autoantigodies by enzyme-linked immunoassay (ELISA), qualitative, and blocking autoantibodies, using a functinal blocking assay for IgG or IgM, quantitative, reported as positive or not detected
0401UCardiology (coronary heart disease CHD), 9 genes (12 variants), targeted variant genotyping, blood, saliva, or buccal swab, algorithm reported as a genetic risk score for a coronary event
0402UInfectious agent (sexually transmitted infection), Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, multiplex amplified probe technique, vaginal, endocervical, or male urine, each pathogen reported as detected or not detected
0403TPreventive behavior change, intensive program of prevention of diabetes using a standardized diabetes prevention program curriculum, provided to individuals in a group setting, minimum 60 minutes, per day
0403UOncology (prostate), mRNA, gene expression profiling of 18 genes, first-catch post-digital rectal examination urine (or processed first-catch urine), algorithm reported as percentage of likelihood of detecting clinically significant prostate cancer
0404TTranscervical uterine fibroid(s) ablation with ultrasound guidance, radiofrequency
0404UOncology (breast), semiquantitative measurement of thymidine kinase activity by immunoassay, serum, results reported as risk of disease progression
0405UOncology (pancreatic), 59 methylation haplotype block markers, next-generation sequencing, plasma, reported as cancer signal detected or not detected
0406UOncology (lung), flow cytometry, sputum, 5 markers (meso-tetra [4-carboxyphenyl] porphyrin [TCPP], CD206, CD66b, CD3, CD19), algorithm reported as likelihood of lung cancer
0407UNephrology (diabetic chronic kidney disease [CKD]), multiplex electrochemiluminescent immunoassay (ECLIA) of soluble tumor necrosis factor receptor 1 (sTNFR1), soluble tumor necrosis receptor 2 (sTNFR2), and kidney injury molecule 1 (KIM-1) combined with clinical data, plasma, algorithm reported as risk for progressive decline in kidney function
0408TInsertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator with transvenous electrodes
0408UInfectious agent antigen detection by bulk acoustic wave biosensor immunoassay, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])
0409TInsertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator only
0410TInsertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; atrial electrode only
0410UOncology (pancreatic), DNA, whole genome sequencing with 5-hydroxymethylcytosine enrichment, whole blood or plasma, algorithm reported as cancer detected or not detected
0411TInsertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; ventricular electrode only
0411UPsychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6 (For additional PLA code with identical clinical descriptor, see 0345U. See Appendix O to determine appropriate code assignment)
0412TRemoval of permanent cardiac contractility modulation system; pulse generator only
0412UBeta amyloid, Aß42/40 ratio, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and qualitative ApoE isoform-specific proteotyping, plasma combined with age, algorithm reported as presence or absence of brain amyloid pathology
0413TRemoval of permanent cardiac contractility modulation system; transvenous electrode (atrial or ventricular)
0413UOncology (hematolymphoid neoplasm), optical genome mapping for copy number alterations, aneuploidy, and balanced/complex structural rearrangements, DNA from blood or bone marrow, report of clinically significant alterations
0414TRemoval and replacement of permanent cardiac contractility modulation system pulse generator only
0414UOncology (lung), augmentative algorithmic analysis of digitized whole slide imaging for 8 genes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1), and KRAS G12C and PD-L1,if performed, formalin-fixed paraffin embedded (FFPE) tissue, reported as positive or negative for each biomarker
0415TRepositioning of previously implanted cardiac contractility modulation transvenous electrode (atrial or ventricular lead)
0415UCardiovascular disease (acute coronary syndrome [ACS]), IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, and MCP-3 by immunoassay combined with age, sex, family history, and personal history of diabetes, blood, algorithm reported as a 5-year (deleted risk) score for ACS
0416TRelocation of skin pocket for implanted cardiac contractility modulation pulse generator
0416UInfectious agent detection by nucleic acid (DNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms, including identification of 20 associated antibiotic-resistance genes, if performed, multiplex amplified probe technique, urine
0417TProgramming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable cardiac contractility modulation system
0417URare diseases (constitutional/heritable disorders), whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, nuclearencoded mitochondrial gene analysis of 335 nuclear genes, including sequence changes, deletions, insertions, and copy number variants analysis, blood or saliva, identification and categorization of mitochondrial disorder–associated genetic variants
0418TInterrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter, implantable cardiac contractility modulation system
0418UOncology (breast), augmentative algorithmic analysis of digitized whole slide imaging of 8 histologic and immunohistochemical features, reported as a recurrence score
0419TDestruction of neurofibroma, extensive (cutaneous, dermal extending into subcutaneous); face, head and neck, greater than 50 neurofibromas
0419UNeuropsychiatry (eg, depression, anxiety), genomic sequence analysis panel, variant analysis of 13 genes, saliva or buccal swab, report of each gene phenotype
0420TDestruction of neurofibroma, extensive (cutaneous, dermal extending into subcutaneous); trunk and extremities, extensive, greater than 100 neurofibromas
0420UOncology (urothelial), mRNA expression profiling by real time quantitative PCR of MDK, HOXA13, CDC2, IGFBP5, and CXCR2 in combination with droplet digital PCR (ddPCR) analysis of 6 single nucleotide polymorphisms (SNPs) genes TERT and FGFR3, urine, algorithm reported as a risk score for urothelial carcinoma
0421UOncology (colorectal) screening, quantitative real time target and signal amplification of 8 RNA markers (GAPDH, SMAD4, ACY1, AREG, CDH1, KRAS, TNFRSF10B, EGLN2) and fecal hemoglobin, algorithm reported as a positive or negative for colorectal cancer risk
0422TTactile breast imaging by computer aided tactile sensors, unilateral or bilateral
0422UOncology (pan solid tumor), analysis of DNA biomarker response to anti cancer therapy using cell free circulating DNA, biomarker comparison to a previous baseline pre treatment cell free circulating DNA analysis using next generation sequencing, algorithm reported as a quantitative change from baseline, including specific alterations, if appropriate
0423UPsychiatry (eg, depression, anxiety), genomic analysis panel, including variant analysis of 26 genes, buccal swab, report including metabolizer status and risk of drug toxicity by condition
0424TInsertion or replacement of neurostimulator system for treatment of central sleep apnea; complete system (transvenous placement of right or left stimulation lead, sensing lead, implantable pulse generator)
0424UOncology (prostate), exosome based analysis of 53 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT qPCR), urine, reported as no molecular evidence, low , moderate or elevated risk of prostate cancer
0425TInsertion or replacement of neurostimulator system for treatment of central sleep apnea; sensing lead only
0425UGenome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis, each comparator genome (eg, parents, siblings)
0426TInsertion or replacement of neurostimulator system for treatment of central sleep apnea; stimulation lead only
0426UGenome (eg, unexplained constitutional or heritable disorder or syndrome), ultra rapid sequence analysis
0427TInsertion or replacement of neurostimulator system for treatment of central sleep apnea; pulse generator only
0427UMonocyte distribution width, whole blood (List separately in addition to code for primary procedure)
0428TRemoval of neurostimulator system for treatment of central sleep apnea; pulse generator only
0428UOncology (breast), targeted hybrid capture genomic sequence analysis panel, circulating tumor DNA (ctDNA) analysis of 56 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutation burden
0429TRemoval of neurostimulator system for treatment of central sleep apnea; sensing lead only
0429UInfectious disease (viral), real-time PCR testing for 14 high-risk HPV types using oropharyngeal swab
0430TRemoval of neurostimulator system for treatment of central sleep apnea; stimulation lead only
0430UGastroenterology, malabsorption evaluation of alpha 1 antitrypsin, calprotectin, pancreatic elastase and reducing substances, feces, quantitative
0431TRemoval and replacement of neurostimulator system for treatment of central sleep apnea, pulse generator only
0431UGlycine receptor alpha1 IgG, serum or cerebrospinal fluid (CSF), live cell binding assay (LCBA), qualitative
0432TRepositioning of neurostimulator system for treatment of central sleep apnea; stimulation lead only
0432UKelch like protein 11 (KLHL11) antibody, serum or cerebrospinal fluid (CSF), cell binding assay, qualitative
0433TRepositioning of neurostimulator system for treatment of central sleep apnea; sensing lead only
0433UOncology (prostate), 5 DNA regulatory markers by quantitative PCR, whole blood, algorithm, including prostate specific antigen, reported as likelihood of cancer
0434TInterrogation device evaluation implanted neurostimulator pulse generator system for central sleep apnea
0434UDrug metabolism (adverse drug reactions and drug response), genomic analysis panel, variant analysis of 25 genes with reported phenotypes
0435TProgramming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; single session
0435UOncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on cytotoxicity percentage observed, minimum of 14 drugs or drug combinations
0436TProgramming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; during sleep study
0436UOncology (lung), plasma analysis of 388 proteins, using aptamer based proteomics technology, predictive algorithm reported as clinical benefit from immune checkpoint inhibitor therapy
0437TImplantation of non biologic or synthetic implant (eg, polypropylene) for fascial reinforcement of the abdominal wall (List separately in addition to code for primary procedure)
0437UPsychiatry (anxiety disorders), mRNA, gene expression profiling by RNA sequencing of 15 biomarkers, whole blood, algorithm reported as predictive risk score
0438UDrug metabolism (adverse drug reactions and drug response), buccal specimen, gene drug interactions, variant analysis of 33 genes, including deletion/duplication analysis of CYP2D6, including reported phenotypes and impacted gene drug interactions
0439TMyocardial contrast perfusion echocardiography, at rest or with stress, for assessment of myocardial ischemia or viability (List separately in addition to code for primary procedure)
0439UCardiology (coronary heart disease [CHD]), DNA, analysis of 5 single-nucleotide polymorphisms (SNPs) (rs11716050 [LOC105376934], rs6560711 [WDR37], s3735222 [SCIN/LOC107986769], rs6820447 [intergenic], and rs9638144 [ESYT2]) and 3 DNA methylation markers (cg00300879 [transcription start site {TSS200} of CNKSR1], cg09552548 [intergenic], and cg14789911 [body of SPATC1L]), qPCR and digital PCR, whole blood, algorithm reported as a 4-tiered risk score for a 3-y
0440TAblation, percutaneous, cryoablation, includes imaging guidance; upper extremity distal/peripheral nerve
0440UCardiology (coronary heart disease [CHD]), DNA, analysis of 10 single-nucleotide polymorphisms (SNPs) (rs710987 [LINC010019], rs1333048 [CDKN2B-AS1], rs12129789 [KCND3], rs942317 [KTN1-AS1], rs1441433 [PPP3CA], rs2869675 [PREX1], rs4639796 [ZBTB41], rs4376434 [LINC00972], rs12714414 [TMEM18], and rs7585056 [TMEM18]) and 6 DNA methylation markers (cg03725309 [SARS1], cg12586707 [CXCL1, cg04988978 [MPO], cg17901584 [DHCR24-DT], cg21161138 [AHRR], and cg12655112 [EHD4]), qPCR and digital PCR, whole blood, algorithm reported as detected or not detected for CHD
0441TAblation, percutaneous, cryoablation, includes imaging guidance; lower extremity distal/peripheral nerve
0441UInfectious disease (bacterial, fungal, or viral infection), semiquantitative biomechanical assessment (via deformability cytometry), whole blood, with algorithmic analysis and result reported as an index
0442TAblation, percutaneous, cryoablation, includes imaging guidance; nerve plexus or other truncal nerve (eg, brachial plexus, pudendal nerve)
0442UInfectious disease (respiratory infection), Myxovirus resistance protein A (MxA) and C-reactive protein (CRP), fingerstick whole blood specimen, each biomarker reported as present or absent
0443TReal time spectral analysis of prostate tissue by fluorescence spectroscopy, including imaging guidance (List separately in addition to code for primary procedure)
0443UNeurofilament light chain (NfL), ultra-sensitive immunoassay, serum or cerebrospinal fluid
0444TInitial placement of a drug eluting ocular insert under one or more eyelids, including fitting, training, and insertion, unilateral or bilateral
0444UOncology (solid organ neoplasia), targeted genomic sequence analysis panel of 361 genes, interrogation for gene fusions, translocations, or other rearrangements, using DNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue, report of clinically significant variant(s)
0445TSubsequent placement of a drug eluting ocular insert under one or more eyelids, including re training, and removal of existing insert, unilateral or bilateral
0445UB-amyloid (Abeta42) and phospho tau (181P) (pTau181), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology
0446TCreation of subcutaneous pocket with insertion of implantable interstitial glucose sensor, including system activation and patient training
0446UAutoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 10 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic risk score for current disease activity
0447TRemoval of implantable interstitial glucose sensor from subcutaneous pocket via incision
0447UAutoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 11 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic prognostic risk score for developing a clinical flare
0448TRemoval of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new implantable sensor, including system activation
0449UCarrier screening for severe inherited conditions (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia), regardless of race or self-identified ancestry, genomic sequence analysis panel, must include analysis of 5 genes (CFTR, SMN1, HBB, HBA1, HBA2)
0450UOncology (multiple myeloma), liquid chromatography with tandem mass spectrometry (LC MS/MS), monoclonal paraprotein sequencing analysis, serum, results reported as baseline presence or absence of detectable clonotypic peptides
0451UOncology (multiple myeloma), LC MS/MS, peptide ion quantification, serum, results compared with baseline to determine monoclonal paraprotein abundance
0452UOncology (bladder), methylated PENK DNA detection by linear target enrichment quantitative methylation specific real time PCR (LTE qMSP), urine, reported as likelihood of bladder cancer
0453UOncology (colorectal cancer), cell free DNA (cfDNA), methylation based quantitative PCR assay (SEPTIN9, IKZF1, BCAT1, Septin9 2, VAV3, BCAN), plasma, reported as presence or absence of circulating tumor DNA (ctDNA)
0454URare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping
0455UInfectious agents (sexually transmitted infection), Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis, multiplex amplified probe technique, vaginal, endocervical, gynecological specimens, oropharyngeal swabs, rectal swabs, female or male urine, each pathogen reported as detected or not detected
0456UAutoimmune (rheumatoid arthritis), next generation sequencing (NGS), gene expression testing of 19 genes, whole blood, with analysis of anti cyclic citrullinated peptides (CCP) levels, combined with sex, patient global assessment, and body mass index (BMI), algorithm reported as a score that predicts nonresponse to tumor necrosis factor inhibitor (TNFi) therapy
0457UPerfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 9 PFAS compounds by LC MS/MS, plasma or serum, quantitative
0458UOncology (breast cancer), S100A8 and S100A9, by enzyme linked immunosorbent assay (ELISA), tear fluid with age, algorithm reported as a risk score
0459Uamyloid (Abeta42) and total tau (tTau), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology
0460UOncology, whole blood or buccal, DNA single nucleotide polymorphism (SNP) genotyping by real time PCR of 24 genes, with variant analysis and reported phenotypes
0461UOncology, pharmacogenomic analysis of single nucleotide polymorphism (SNP) genotyping by real time PCR of 24 genes, whole blood or buccal swab, with variant analysis, including impacted gene drug interactions and reported phenotypes
0462UMelatonin levels test, sleep study, 7 or 9 sample melatonin profile (cortisol optional), enzyme linked immunosorbent assay (ELISA), saliva, screening/preliminary
0463UOncology (cervix), mRNA gene expression profiling of 14 biomarkers (E6 and E7 of the highest risk human papillomavirus [HPV] types 16, 18, 31, 33, 45, 52, 58), by real time nucleic acid sequence based amplification (NASBA), exo or endocervical epithelial cells, algorithm reported as positive or negative for increased risk of cervical dysplasia or cancer for each biomarker
0464TVisual evoked potential, testing for glaucoma, with interpretation and report
0464UOncology (colorectal) screening, quantitative real time target and signal amplification, methylated DNA markers, including LASS4, LRRC4 and PPP2R5C, a reference marker ZDHHC1, and a protein marker (fecal hemoglobin), utilizing stool, algorithm reported as a positive or negative result
0465TSuprachoroidal injection of a pharmacologic agent (does not include supply of medication)
0465UOncology (urothelial carcinoma), DNA, quantitative methylation specific PCR of 2 genes (ONECUT2, VIM), algorithmic analysis reported as positive or negative
0466UCardiology (coronary artery disease [CAD]), DNA, genome wide association studies (564856 single nucleotide polymorphisms [SNPs], targeted variant genotyping), patient lifestyle and clinical data, buccal swab, algorithm reported as polygenic risk to acquired heart disease
0467UOncology (bladder), DNA, next generation sequencing (NGS) of 60 genes and whole genome aneuploidy, urine, algorithms reported as minimal residual disease (MRD) status positive or negative and quantitative disease burden
0468UHepatology (nonalcoholic steatohepatitis [NASH]), miR 34a 5p, alpha 2 macroglobulin, YKL40, HbA1c, serum and whole blood, algorithm reported as a single score for NASH activity and fibrosis
0469TRetinal polarization scan, ocular screening with on site automated results, bilateral
0469URare diseases (constitutional/heritable disorders), whole genome sequence analysis for chromosomal abnormalities, copy number variants, duplications/deletions, inversions, unbalanced translocations, regions of homozygosity (ROH), inheritance pattern that indicate uniparental disomy (UPD), and aneuploidy, fetal sample (amniotic fluid, chorionic villus sample, or products of conception), identification and categorization of genetic variants, diagnostic report of fetal results based on phenotype with maternal sample and paternal sample, if performed, as comparators and/or maternal cell contamination
0470TOptical coherence tomography (OCT) for microstructural and morphological imaging of skin, image acquisition, interpretation, and report; first lesion
0470UOncology (oropharyngeal), detection of minimal residual disease by next generation sequencing (NGS) based quantitative evaluation of 8 DNA targets, cell free HPV 16 and 18 DNA from plasma
0471TOptical coherence tomography (OCT) for microstructural and morphological imaging of skin, image acquisition, interpretation, and report; each additional lesion (List separately in addition to code for primary procedure)
0472UCarbonic anhydrase VI (CA VI), parotid specific/secretory protein (PSP) and salivary protein (SP1) IgG, IgM, and IgA antibodies, enzyme linked immunosorbent assay (ELISA), semiqualitative, blood, reported as predictive evidence of early Sjögren syndrome
0474UHereditary pan cancer (eg, hereditary sarcomas, hereditary endocrine tumors, hereditary neuroendocrine tumors, hereditary cutaneous melanoma), genomic sequence analysis panel of 88 genes with 20 duplications/deletions using next generation sequencing (NGS), Sanger sequencing, blood or saliva, reported as positive or negative for germline variants, each gene
0475TRecording of fetal magnetic cardiac signal using at least 3 channels; patient recording and storage, data scanning with signal extraction, technical analysis and result, as well as supervision, review, and interpretation of report by a physician or other qualified health care professional
0475UHereditary prostate cancer related disorders, genomic sequence analysis panel using next generation sequencing (NGS), Sanger sequencing, multiplex ligation dependent probe amplification (MLPA), and array comparative genomic hybridization (CGH), evaluation of 23 genes and duplications/deletions when indicated, pathologic mutations reported with a genetic risk score for prostate cancer
0476TRecording of fetal magnetic cardiac signal using at least 3 channels; patient recording, data scanning, with raw electronic signal transfer of data and storage
0476UDrug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [ADHD], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis and reported phenotypes
0477TRecording of fetal magnetic cardiac signal using at least 3 channels; signal extraction, technical analysis, and result
0477UDrug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder,attention deficit hyperactivity disorder [ADHD], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis, including impacted gene drug interactions and reported phenotypes
0478TRecording of fetal magnetic cardiac signal using at least 3 channels; review, interpretation, report by physician or other qualified health care professional
0479UTau, phosphorylated, pTau217
0480UInfectious disease (bacteria, viruses, fungi, and parasites), cerebrospinal fluid (CSF), metagenomic next generation sequencing (DNA and RNA), bioinformatic analysis, with positive pathogen identification
0481TInjection(s), autologous white blood cell concentrate (autologous protein solution), any site, including image guidance, harvesting and preparation, when performed
0482UObstetrics (preeclampsia), biochemical assay of soluble fmslike tyrosine kinase 1 (sFlt 1) and placental growth factor (PlGF), serum, ratio reported for sFlt1/PlGF, with risk of progression for preeclampsia with severe features within 2 weeks
0483UInfectious disease (Neisseria gonorrhoeae), sensitivity, ciprofloxacin resistance (gyrA S91F point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of fluoroquinolone resistance
0484UInfectious disease (Mycoplasma genitalium), macrolide sensitivity (23S rRNA point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of macrolide resistance
0485TOptical coherence tomography (OCT) of middle ear, with interpretation and report; unilateral
0485UOncology (solid tumor), cell free DNA and RNA by next generation sequencing, interpretative report for germline mutations, clonal hematopoiesis of indeterminate potential, and tumor derived single nucleotide variants, small insertions/deletions, copy number alterations, fusions, microsatellite instability, and tumor mutational burden
0486TOptical coherence tomography (OCT) of middle ear, with interpretation and report; bilateral
0486UOncology (pan solid tumor), nextgeneration sequencing analysis of tumor methylation markers present in cell free circulating tumor DNA, algorithm reported as quantitative measurement of methylation as a correlate of tumor fraction
0487TBiomechanical mapping, transvaginal, with report
0487UOncology (solid tumor), cell free circulating DNA, targeted genomic sequence analysis panel of 84 genes, interrogation for sequence variants, aneuploidycorrected gene copy number amplifications and losses, gene rearrangements, and microsatellite instability
0488TPreventive behavior change, online/electronic structured intensive program for prevention of diabetes using a standardized diabetes prevention program curriculum, provided to an individual, per 30 days
0488UObstetrics (fetal antigen noninvasive prenatal test), cellfree DNA sequence analysis for detection of fetal presence or absence of 1 or more of the Rh, C, c, D, E, Duffy (Fya), or Kell (K) antigen in alloimmunized pregnancies, reported as selected antigen(s) detected or not detected
0489TAutologous adipose derived regenerative cell therapy for scleroderma in the hands; adipose tissue harvesting, isolation and preparation of harvested cells including incubation with cell dissociation enzymes, removal of non viable cells and debris, determination of concentration and dilution of regenerative cells
0489UObstetrics (single gene noninvasive prenatal test), cellfree DNA sequence analysis of 1 or more targets (eg, CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants, and relative mutation dosage analysis based on molecular counts to determine fetal inheritance of maternal mutation, algorithm reported as a fetal risk score for the condition (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia)
0490TAutologous adipose derived regenerative cell therapy for scleroderma in the hands; multiple injections in one or both hands
0490UOncology (cutaneous or uveal melanoma), circulating tumor cell selection, morphological characterization and enumeration based on differential CD146, high molecular weight melanomaassociated antigen, CD34 and CD45 protein biomarkers, peripheral blood
0491TAblative laser treatment, non contact, full field and fractional ablation, open wound, per day, total treatment surface area; first 20 sq cm or less
0491UOncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of estrogen receptor (ER) protein biomarker expressing cells, peripheral blood
0492TAblative laser treatment, non contact, full field and fractional ablation, open wound, per day, total treatment surface area; each additional 20 sq cm, or part thereof (List separately in addition to code for primary procedure)
0492UOncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of PD L1 protein biomarker expressing cells, peripheral blood
0493TContact near infrared spectroscopy studies of lower extremity wounds (eg, for oxyhemoglobin measurement)
0494TSurgical preparation and cannulation of marginal (extended) cadaver donor lung(s) to ex vivo organ perfusion system, including decannulation, separation from the perfusion system, and cold preservation of the allograft prior to implantation, when performed
0494URed blood cell antigen (fetal RhD gene analysis), next generation sequencing of circulating cell free DNA (cfDNA) of blood in pregnant individuals known to be RhD negative, reported as positive or negative
0495TInitiation and monitoring marginal (extended) cadaver donor lung(s) organ perfusion system by physician or qualified health care professional, including physiological and laboratory assessment (eg, pulmonary artery flow, pulmonary artery pressure, left atrial pressure, pulmonary vascular resistance, mean/peak and plateau airway pressure, dynamic compliance and perfusate gas analysis), including bronchoscopy and X ray when performed; first two hours in sterile field
0495UOncology (prostate), analysis of circulating plasma proteins (tPSA, fPSA, KLK2, PSP94, and GDF15), germline polygenic risk score (60 variants), clinical information (age, family history of prostate cancer, prior negative prostate biopsy), algorithm reported as risk of likelihood of detecting clinically significant prostate cancer
0496TInitiation and monitoring marginal (extended) cadaver donor lung(s) organ perfusion system by physician or qualified health care professional, including physiological and laboratory assessment (eg, pulmonary artery flow, pulmonary artery pressure, left atrial pressure, pulmonary vascular resistance, mean/peak and plateau airway pressure, dynamic compliance and perfusate gas analysis), including bronchoscopy and X ray when performed; each additional hour (List separately in addition to code for primary procedure)
0496UOncology (colorectal), cell free DNA, 8 genes for mutations, 7 genes for methylation by real time RT PCR, and 4 proteins by enzyme linked immunosorbent assay, blood, reported positive or negative for colorectal cancer or advanced adenoma risk
0497TExternal patient activated, physician or other qualified health care professional prescribed, electrocardiographic rhythm derived event recorder without 24 hour attended monitoring; in office connection
0497UOncology (prostate), mRNA geneexpression profiling by real time RT PCR of 6 genes (FOXM1, MCM3, MTUS1, TTC21B, ALAS1, and PPP2CA), utilizing formalinfixed paraffin embedded (FFPE) tissue, algorithm reported as a risk score for prostate cancer
0498TExternal patient activated, physician or other qualified health care professional prescribed, electrocardiographic rhythm derived event recorder without 24 hour attended monitoring; review and interpretation by a physician or other qualified health care professional per 30 days with at least one patient generated triggered event
0498UOncology (colorectal), nextgeneration sequencing for mutation detection in 43 genes and methylation pattern in 45 genes, blood, and formalin fixed paraffin embedded (FFPE) tissue, report of variants and methylation pattern with interpretation
0499TCystourethroscopy, with mechanical dilation and urethral therapeutic drug delivery for urethral stricture or stenosis, including fluoroscopy, when performed
0499UOncology (colorectal and lung), DNA from formalin fixed paraffinembedded (FFPE) tissue, nextgeneration sequencing of 8 genes (NRAS, EGFR, CTNNB1, PIK3CA, APC, BRAF, KRAS, and TP53), mutation detection
0500TInfectious agent detection by nucleic acid (DNA or RNA), Human Papillomavirus (HPV) for five or more separately reported high risk HPV types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) (ie, genotyping)
0500UAutoinflammatory disease (VEXAS syndrome), DNA, UBA1 gene mutations, targeted variant analysis (M41T, M41V, M41L, c.118 2A>C, c.118 1G>C, c.118 9_118 2del, S56F, S621C)
0501UOncology (colorectal), blood, quantitative measurement of cellfree DNA (cfDNA)
0502UHuman papillomavirus (HPV), E6/E7 markers for high risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), cervical cells, branched chain capture hybridization, reported as negative or positive for high risk for HPV
0503UNeurology (Alzheimer disease), beta amyloid (AI 40, AI 42, AI 42/40 ratio) and tau protein (ptau217, np tau217, ptau217/nptau217 ratio), blood, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC MS/MS), algorithm score reported as likelihood of positive or negative for amyloid plaques
0504UInfectious disease (urinary tract infection), identification of 17 pathologic organisms, urine, realtime PCR, reported as positive or negative for each organism
0505TEndovenous femoral popliteal arterial revascularization, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed, with crossing of the occlusive lesion in an extraluminal fashion
0505UInfectious disease (vaginal infection), identification of 32 pathogenic organisms, swab, real time PCR, reported as positive or negative for each organism
0506TMacular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report
0506UGastroenterology (Barrett's esophagus), esophageal cells, DNA methylation analysis by next generation sequencing of at least 89 differentially methylated genomic regions, algorithm reported as likelihood for Barrett's esophagus
0507TNear infrared dual imaging (ie, simultaneous reflective and transilluminated light) of meibomian glands, unilateral or bilateral, with interpretation and report
0507UOncology (ovarian), DNA, wholegenome sequencing with 5 hydroxymethylcytosine (5hmC) enrichment, using whole blood or plasma, algorithm reported as cancer detected or not detected
0508TPulse echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia
0508UTransplantation medicine, quantification of donor derived cell free DNA using 40 singlenucleotide polymorphisms (SNPs), plasma, and urine, initial evaluation reported as percentage of donor derived cellfree DNA with risk for active rejection
0509TElectroretinography (ERG) with interpretation and report, pattern (PERG)
0509UTransplantation medicine, quantification of donor derived cell free DNA using up to 12 single nucleotide polymorphisms (SNPs) previously identified, plasma, reported as percentage of donor derived cell free DNA with risk for active rejection
0510TRemoval of sinus tarsi implant
0510UOncology (pancreatic cancer), augmentative algorithmic analysis of 16 genes from previously sequenced RNA wholetranscriptome data, reported as probability of predicted molecular subtype
0511TRemoval and reinsertion of sinus tarsi implant
0511UOncology (solid tumor), tumor cell culture in 3D microenvironment, 36 or more drug panel, reported as tumor response prediction for each drug
0512TExtracorporeal shock wave for integumentary wound healing, including topical application and dressing care; initial wound
0512UOncology (prostate), augmentative algorithmic analysis of digitized whole slide imaging of histologic features for microsatellite instability (MSI) status, formalin fixed paraffinembedded (FFPE) tissue, reported as increased or decreased probability of MSI high (MSI H)
0513TExtracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; each additional wound (List separately in addition to code for primary procedure)
0513UOncology (prostate), augmentative algorithmic analysis of digitized whole slide imaging of histologic features for microsatellite instability (MSI) and homologous recombination deficiency (HRD) status, formalinfixed paraffin embedded (FFPE) tissue, reported as increased or decreased probability of each biomarker
0514TIntraoperative visual axis identification using patient fixation (List separately in addition to code for primary procedure)
0514UGastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of adalimumab (ADL) levels in venous serum in patients undergoing adalimumab therapy, results reported as a numerical value as micrograms per milliliter (Aug/mL)
0515TInsertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; complete system (includes electrode and generator [transmitter and battery])
0515UGastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of infliximab (IFX) levels in venous serum in patients undergoing infliximab therapy, results reported as a numerical value as micrograms per milliliter (Aug/mL)
0516TInsertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; electrode only
0516UDrug metabolism, whole blood, pharmacogenomic genotyping of 40 genes and CYP2D6 copy number variant analysis, reported as metabolizer status
0517TInsertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; pulse generator component(s) (battery and/or transmitter) only
0517UTherapeutic drug monitoring, 80 or more psychoactive drugs or substances, LC MS/MS, plasma, qualitative and quantitative therapeutic minimally and maximally effective dose of prescribed and non prescribed medications
0518TRemoval of only pulse generator component(s) (battery and/or transmitter) of wireless cardiac stimulator for left ventricular pacing
0518UTherapeutic drug monitoring, 90 or more pain and mental health drugs or substances, LC MS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non prescribed medications
0519TRemoval and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter)
0519UTherapeutic drug monitoring, medications specific to pain, depression, and anxiety, LCMS/MS, plasma, 110 or more drugs or substances, qualitative and quantitative therapeutic minimally effective range of prescribed, non prescribed, and illicit medications in circulation
0520TRemoval and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter), including placement of a new electrode
0520UTherapeutic drug monitoring, 200 or more drugs or substances, LCMS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non prescribed medications
0521TInterrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per patient encounter, wireless cardiac stimulator for left ventricular pacing
0522TProgramming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, wireless cardiac stimulator for left ventricular pacing
0523TIntraprocedural coronary fractional flow reserve (FFR) with 3D functional mapping of color coded FFR values for the coronary tree, derived from coronary angiogram data, for real time review and interpretation of possible atherosclerotic stenosis(es) intervention (List separately in addition to code for primary procedure)
0524TEndovenous catheter directed chemical ablation with balloon isolation of incompetent extremity vein, open or percutaneous, including all vascular access, catheter manipulation, diagnostic imaging, imaging guidance and monitoring
0525TInsertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)
0526TInsertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only
0527TInsertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only
0528TProgramming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report
0529TInterrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report
0530TRemoval of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor)
0531TRemoval of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; electrode only
0532TRemoval of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; implantable monitor only
0533TContinuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; includes set up, patient training, configuration of monitor, data upload, analysis and initial report configuration, download review, interpretation and report
0534TContinuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; set up, patient training, configuration of monitor
0535TContinuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; data upload, analysis and initial report configuration
0536TContinuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; download review, interpretation and report
0541TMyocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic field time series images, quantitative analysis of magnetic dipoles, machine learning derived clinical scoring, and automated report generation, single study;
0542TMyocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic field time series images, quantitative analysis of magnetic dipoles, machine learning derived clinical scoring, and automated report generation, single study; interpretation and report
0543TTransapical mitral valve repair, including transthoracic echocardiography, when performed, with placement of artificial chordae tendineae
0544TTranscatheter mitral valve annulus reconstruction, with implantation of adjustable annulus reconstruction device, percutaneous approach including transseptal puncture
0545TTranscatheter tricuspid valve annulus reconstruction with implantation of adjustable annulus reconstruction device, percutaneous approach
0546TRadiofrequency spectroscopy, real time, intraoperative margin assessment, at the time of partial mastectomy, with report
0547TBone material quality testing by microindentation(s) of the tibia(s), with results reported as a score
0553TPercutaneous transcatheter placement of iliac arteriovenous anastomosis implant, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention
0554TBone strength and fracture risk using finite element analysis of functional data and bone mineral density utilizing data from a computed tomography scan; retrieval and transmission of the scan data, assessment of bone strength and fracture risk and bone mineral density, interpretation and report
0555TBone strength and fracture risk using finite element analysis of functional data and bone mineral density utilizing data from a computed tomography scan; retrieval and transmission of the scan data
0556TBone strength and fracture risk using finite element analysis of functional data and bone mineral density utilizing data from a computed tomography scan; assessment of bone strength and fracture risk and bone mineral density
0557TBone strength and fracture risk using finite element analysis of functional data and bone mineral density utilizing data from a computed tomography scan; interpretation and report
0558TComputed tomography scan taken for the purpose of biomechanical computed tomography analysis
0559TAnatomic model 3D printed from image data set(s); first individually prepared and processed component of an anatomic structure
0560TAnatomic model 3D printed from image data set(s); each additional individually prepared and processed component of an anatomic structure (List separately in addition to code for primary procedure)
0561TAnatomic guide 3D printed and designed from image data set(s); first anatomic guide
0562TAnatomic guide 3D printed and designed from image data set(s); each additional anatomic guide (List separately in addition to code for primary procedure)
0563TEvacuation of meibomian glands, using heat delivered through wearable, open eye eyelid treatment devices and manual gland expression, bilateral
0564TOncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on percent of cytotoxicity observed, a minimum of 14 drugs or drug combinations
0565TAutologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular implant creation
0566TAutologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; injection of cellular implant into knee joint including ultrasound guidance, unilateral
0567TPermanent fallopian tube occlusion with degradable biopolymer implant, transcervical approach, including transvaginal ultrasound
0568TIntroduction of mixture of saline and air for sonosalpingography to confirm occlusion of fallopian tubes, transcervical approach, including transvaginal ultrasound and pelvic ultrasound
0569TTranscatheter tricuspid valve repair, percutaneous approach; initial prosthesis
0570TTranscatheter tricuspid valve repair, percutaneous approach; each additional prosthesis during same session (List separately in addition to code for primary procedure)
0571TInsertion or replacement of implantable cardioverter defibrillator system with substernal electrode(s), including all imaging guidance and electrophysiological evaluation (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters), when performed
0572TInsertion of substernal implantable defibrillator electrode
0573TRemoval of substernal implantable defibrillator electrode
0574TRepositioning of previously implanted substernal implantable defibrillator pacing electrode
0575TProgramming device evaluation (in person) of implantable cardioverter defibrillator system with substernal electrode, with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional
0576TInterrogation device evaluation (in person) of implantable cardioverter defibrillator system with substernal electrode, with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter
0577TElectrophysiologic evaluation of implantable cardioverter-defibrillator system with substernal electrode (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters)
0578TInterrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional
0579TInterrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results
0580TRemoval of substernal implantable defibrillator pulse generator only
0581TAblation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance when performed, unilateral
0582TTransurethral ablation of malignant prostate tissue by high energy water vapor thermotherapy, including intraoperative imaging and needle guidance
0583TTympanostomy (requiring insertion of ventilating tube), using an automated tube delivery system, iontophoresis local anesthesia
0591THealth and well being coaching face to face; individual, initial assessment
0592THealth and well being coaching face to face; individual, follow up session, at least 30 minutes
0593THealth and well being coaching face to face; group (2 or more individuals), at least 30 minutes
0594TOsteotomy, humerus, with insertion of an externally controlled intramedullary lengthening device, including intraoperative imaging, initial and subsequent alignment assessments, computations of adjustment schedules, and management of the intramedullary lengthening device
0596TTemporary female intraurethral valve pump (ie, voiding prosthesis); initial insertion, including urethral measurement
0597TTemporary female intraurethral valve-pump (ie, voiding prosthesis); replacement
0598TNoncontact real time fluorescence wound imaging, for bacterial presence, location, and load, per session; first anatomic site (eg, lower extremity)
0599TNoncontact real time fluorescence wound imaging, for bacterial presence, location, and load, per session; each additional anatomic site (eg, upper extremity) (List separately in addition to code for primary procedure)
0600TAblation, irreversible electroporation; 1 or more tumors per organ, including imaging guidance, when performed, percutaneous
0601TAblation, irreversible electroporation; 1 or more tumors per organ, including fluoroscopic and ultrasound guidance, when performed, open
0602TGlomerular filtration rate (GFR) measurement(s), transdermal, including sensor placement and administration of a single dose of fluorescent pyrazine agent
0603TGlomerular filtration rate (GFR) monitoring, transdermal, including sensor placement and administration of more than one dose of fluorescent pyrazine agent, each 24 hours
0604TOptical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center, unilateral or bilateral; initial device provision, set-up and patient education on use of equipment
0605TOptical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center, unilateral or bilateral; remote surveillance center technical support, data analyses and reports, with a minimum of 8 daily recordings, each 30 days
0606TOptical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center, unilateral or bilateral; review, interpretation and report by the prescribing physician or other qualified health care professional of remote surveillance center data analyses, each 30 days
0607TRemote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24 hour attended surveillance center; set up and patient education on use of equipment
0608TRemote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24 hour attended surveillance center; analysis of data received and transmission of reports to the physician or other qualified health care professional
0609TMagnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); acquisition of single voxel data, per disc, on biomarkers (ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs
0610TMagnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); transmission of biomarker data for software analysis
0611TMagnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); postprocessing for algorithmic analysis of biomarker data for determination of relative chemical differences between discs
0612TMagnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); interpretation and report
0613TPercutaneous transcatheter implantation of interatrial septal shunt device, including right and left heart catheterization, intracardiac echocardiography, and imaging guidance by the proceduralist, when performed
0614TRemoval and replacement of substernal implantable defibrillator pulse generator
0615TEye movement analysis without spatial calibration, with interpretation and report
0616TInsertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; without removal of crystalline lens or intraocular lens, without insertion of intraocular lens
0617TInsertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; with removal of crystalline lens and insertion of intraocular lens
0618TInsertion of iris prosthesis, including suture fixation and repair or removal of iris, when performed; with secondary intraocular lens placement or intraocular lens exchange
0619TCystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed
0620TEndovascular venous arterialization, tibial or peroneal vein, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed
0621TTrabeculostomy ab interno by laser; (Do not report 0621T, 0622T in conjunction with 92020, 0730T)
0622TTrabeculostomy ab interno by laser; with use of ophthalmic endoscope (Do not report 0621T, 0622T in conjunction with 92020, 0730T)
0623TAutomated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission, computerized analysis of data, with review of computerized analysis output to reconcile discordant data, interpretation and report
0624TAutomated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission
0625TAutomated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; computerized analysis of data from coronary computed tomographic angiography
0626TAutomated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; review of computerized analysis output to reconcile discordant data, interpretation and report
0627TPercutaneous injection of allogeneic cellular and/or tissue based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; first level
0628TPercutaneous injection of allogeneic cellular and/or tissue based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; each additional level (List separately in addition to code for primary procedure)
0629TPercutaneous injection of allogeneic cellular and/or tissue based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; first level
0630TPercutaneous injection of allogeneic cellular and/or tissue based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; each additional level (List separately in addition to code for primary procedure)
0631TTranscutaneous visible light hyperspectral imaging measurement of oxyhemoglobin, deoxyhemoglobin, and tissue oxygenation, with interpretation and report, per extremity
0632TPercutaneous transcatheter ultrasound ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance
0633TComputed tomography, breast, including 3D rendering, when performed, unilateral; without contrast material
0634TComputed tomography, breast, including 3D rendering, when performed, unilateral; with contrast material(s)
0635TComputed tomography, breast, including 3D rendering, when performed, unilateral; without contrast, followed by contrast material(s)
0636TComputed tomography, breast, including 3D rendering, when performed, bilateral; without contrast material(s)
0637TComputed tomography, breast, including 3D rendering, when performed, bilateral; with contrast material(s)
0638TComputed tomography, breast, including 3D rendering, when performed, bilateral; without contrast, followed by contrast material(s)
0639TWireless skin sensor thermal anisotropy measurement(s) and assessment of flow in cerebrospinal fluid shunt, including ultrasound guidance, when performed
0640TNoncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO2]); image acquisition, interpretation and report, each flap or wound
0641TNoncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO2]); image acquisition only, each flap or wound
0642TNoncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO2]); interpretation and report only, each flap or wound
0643TTranscatheter left ventricular restoration device implantation including right and left heart catheterization and left ventriculography when performed, arterial approach
0644TTranscatheter removal or debulking of intracardiac mass (eg, vegetations, thrombus) via suction (eg, vacuum, aspiration) device, percutaneous approach, with intraoperative reinfusion of aspirated blood, including imaging guidance, when performed
0645TTranscatheter implantation of coronary sinus reduction device including vascular access and closure, right heart catheterization, venous angiography, coronary sinus angiography, imaging guidance, and supervision and interpretation, when performed
0646TTranscatheter tricuspid valve implantation/replacement (TTVI) with prosthetic valve, percutaneous approach, including right heart catheterization, temporary pacemaker insertion, and selective right ventricular or right atrial angiography, when performed
0647TInsertion of gastrostomy tube, percutaneous, with magnetic gastropexy, under ultrasound guidance, image documentation and report
0648TQuantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure) during the same session; single organ
0649TQuantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure); single organ (List separately in addition to code for primary procedure)
0650TProgramming device evaluation (remote) of subcutaneous cardiac rhythm monitor system, with iterative adjustment of the implantable device to test the function of the device and select optimal permanently programmed values with analysis, review and report by a physician or other qualified health care professional
0651TMagnetically controlled capsule endoscopy, esophagus through stomach, including intraprocedural positioning of capsule, with interpretation and report
0652TEsophagogastroduodenoscopy, flexible, transnasal; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)
0653TEsophagogastroduodenoscopy, flexible, transnasal; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure) with biopsy, single or multiple
0654TEsophagogastroduodenoscopy, flexible, transnasal; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure) with insertion of intraluminal tube or catheter
0655TTransperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound imaging
0656TVertebral body tethering, anterior; up to 7 vertebral segments
0657TVertebral body tethering, anterior; 8 or more vertebral segments
0658TElectrical impedance spectroscopy of 1 or more skin lesions for automated melanoma risk score
0659TTranscatheter intracoronary infusion of supersaturated oxygen in conjunction with percutaneous coronary revascularization during acute myocardial infarction, including catheter placement, imaging guidance (eg, fluoroscopy), angiography, and radiologic supervision and interpretation
0660TImplantation of anterior segment intraocular nonbiodegradable drug-eluting system, internal approach
0661TRemoval and reimplantation of anterior segment intraocular nonbiodegradable drug-eluting implant
0662TScalp cooling, mechanical; initial measurement and calibration of cap
0663TScalp cooling, mechanical; placement of device, monitoring, and removal of device (List separately in addition to code for primary procedure)
0664TDonor hysterectomy (including cold preservation); open, from cadaver donor
0665TDonor hysterectomy (including cold preservation); open, from living donor
0666TDonor hysterectomy (including cold preservation); laparoscopic or robotic, from living donor
0667TDonor hysterectomy (including cold preservation); recipient uterus allograft transplantation from cadaver or living donor
0668TBackbench standard preparation of cadaver or living donor uterine allograft prior to transplantation, including dissection and removal of surrounding soft tissues and preparation of uterine vein(s) and uterine artery(ies), as necessary
0669TBackbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; venous anastomosis, each
0670TBackbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; arterial anastomosis, each
0672TEndovaginal cryogen cooled, monopolar radiofrequency remodeling of the tissues surrounding the female bladder neck and proximal urethra for urinary incontinence
0673TAblation, benign thyroid nodule(s), percutaneous, laser, including imaging guidance
0674TLaparoscopic insertion of new or replacement of permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including an implantable pulse generator and diaphragmatic lead(s)
0675TLaparoscopic insertion of new or replacement of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; first lead
0676TLaparoscopic insertion of new or replacement of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; each additional lead (Lis
0677TLaparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; first repositioned lead
0678TLaparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; each additional repositioned lead (List sep
0679TLaparoscopic removal of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function
0680TInsertion or replacement of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing lead(s)
0681TRelocation of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing dual leads
0682TRemoval of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function
0683TProgramming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care
0684TPeri procedural device evaluation (in person) and programming of device system parameters before or after a surgery, procedure, or test with analysis, review, and report by a physician or other qualified health care professional, permanent implantable syn
0685TInterrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, including connection, recording and disconnection per patient encounter, permanent implantable synchronized diaphragma
0686THistotripsy (ie, non thermal ablation via acoustic energy delivery) of malignant hepatocellular tissue, including image guidance
0687TTreatment of amblyopia using an online digital program; device supply, educational set up, and initial session
0688TTreatment of amblyopia using an online digital program; assessment of patient performance and program data by physician or other qualified health care professional, with report, per calendar month
0689TQuantitative ultrasound tissue characterization (non elastographic), including interpretation and report, obtained without diagnostic ultrasound examination of the same anatomy (eg, organ, gland, tissue, target structure)
0690TQuantitative ultrasound tissue characterization (non elastographic), including interpretation and report, obtained with diagnostic ultrasound examination of the same anatomy (eg, organ, gland, tissue, target structure) (List separately in addition to code
0691TAutomated analysis of an existing computed tomography study for vertebral fracture(s), including assessment of bone density when performed, data preparation, interpretation, and report
0692TTherapeutic ultrafiltration
0693TComprehensive full body computer based markerless 3D kinematic and kinetic motion analysis and report
0694T3 dimensional volumetric imaging and reconstruction of breast or axillary lymph node tissue, each excised specimen, 3 dimensional automatic specimen reorientation, interpretation and report, real time intraoperative
0695TBody surface activation mapping of pacemaker or pacing cardioverter defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of implant or
0696TBody surface activation mapping of pacemaker or pacing cardioverter defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of follow up
0697TQuantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the
0698TQuantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the sa
0700TMolecular fluorescent imaging of suspicious nevus; first lesion
0701TMolecular fluorescent imaging of suspicious nevus; each additional lesion (List separately in addition to code for primary procedure)
0702TRemote therapeutic monitoring of a standardized online digital cognitive behavioral therapy program ordered by a physician or other qualified health care professional; supply and technical support, per 30 days
0703TRemote therapeutic monitoring of a standardized online digital cognitive behavioral therapy program ordered by a physician or other qualified health care professional; management services by physician or other qualified health care professional, per calen
0704TRemote treatment of amblyopia using an eye tracking device; device supply with initial set-up and patient education on use of equipment
0705TRemote treatment of amblyopia using an eye tracking device; surveillance center technical support including data transmission with analysis, with a minimum of 18 training hours, each 30 days
0706TRemote treatment of amblyopia using an eye tracking device; interpretation and report by physician or other qualified health care professional, per calendar month
0707TInjection(s), bone-substitute material (eg, calcium phosphate) into subchondral bone defect (ie, bone marrow lesion, bone bruise, stress injury, microtrabecular fracture), including imaging guidance and arthroscopic assistance for joint visualization
0708TIntradermal cancer immunotherapy; preparation and initial injection
0709TIntradermal cancer immunotherapy; each additional injection
0710TNoninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; including data preparation and transmission, quantification of the structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability, data review, interpretation and report
0711TNoninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data preparation and transmission
0712TNoninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; quantification of the structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability
0713TNoninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data review, interpretation and report
0714TTransperineal laser ablation of benign prostatic hyperplasia, including imaging guidance
0715TPercutaneous transluminal coronary lithotripsy (List separately in addition to code for primary procedure)
0716TCardiac acoustic waveform recording with automated analysis and generation of coronary artery disease risk score
0717TAutologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; adipose tissue harvesting, isolation and preparation of harvested cells, including incubation with cell dissociation enzymes, filtration, washing and concentration of ADRCs
0718TAutologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; injection into supraspinatus tendon including ultrasound guidance, unilateral
0719TPosterior vertebral joint replacement, including bilateral facetectomy, laminectomy, and radical discectomy, including imaging guidance, lumbar spine, single segment
0720TPercutaneous electrical nerve field stimulation, cranial nerves, without implantation
0721TQuantitative computed tomography (CT) tissue characterization, including interpretation and report, obtained without concurrent CT examination of any structure contained in previously acquired diagnostic imaging
0722TQuantitative computed tomography (CT) tissue characterization, including interpretation and report, obtained with concurrent CT examination of any structure contained in the concurrently acquired diagnostic imaging dataset (List separately in addition to code for primary procedure)
0723TQuantitative magnetic resonance cholangiopancreatography (QMRCP) including data preparation and transmission, interpretation and report, obtained without diagnostic magnetic resonance imaging (MRI) examination of the same anatomy (eg, organ, gland, tissue, target structure) during the same session
0724TQuantitative magnetic resonance cholangiopancreatography (QMRCP) including data preparation and transmission, interpretation and report, obtained with diagnostic magnetic resonance imaging (MRI) examination of the same anatomy (eg, organ, gland, tissue, target structure) (List separately in addition to code for primary procedure)
0725TVestibular device implantation, unilateral
0726TRemoval of implanted vestibular device, unilateral
0727TRemoval and replacement of implanted vestibular device, unilateral
0728TDiagnostic analysis of vestibular implant, unilateral; with initial programming
0729TDiagnostic analysis of vestibular implant, unilateral; with subsequent programming
0730TTrabeculotomy by laser, including optical coherence tomography (OCT) guidance
0731TAugmentative AI-based facial phenotype analysis with report
0732TImmunotherapy administration with electroporation, intramuscular
0733TRemote real-time, motion capture-based neurorehabilitative therapy ordered by a physician or other qualified health care professional; supply and technical support, per 30 days
0734TRemote real-time, motion capture-based neurorehabilitative therapy ordered by a physician or other qualified health care professional; treatment management services by a physician or other qualified health care professional, per calendar month
0735TPreparation of tumor cavity, with placement of a radiation therapy applicator for intraoperative radiation therapy (IORT) concurrent with primary craniotomy (List separately in addition to code for primary procedure)
0736TColonic lavage, 35 or more liters of water, gravity-fed, with induced defecation, including insertion of rectal catheter
0737TXenograft implantation into the articular surface
0738TTreatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed magnetic resonance imaging (MRI) examination
0739TAblation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and
0740TRemote autonomous algorithm-based recommendation system for insulin dose calculation and titration; initial set-up and patient education
0741TRemote autonomous algorithm-based recommendation system for insulin dose calculation and titration; initial set-up and patient education; provision of software, data collection, transmission, and storage, each 30 days
0742TAbsolute quantitation of myocardial blood flow (AQMBF), single-photon emission computed tomography (SPECT), with exercise or pharmacologic stress, and at rest, when performed (List separately in addition to code for primary procedure)
0743TBone strength and fracture risk using finite element analysis of functional data and bone-mineral density, with concurrent vertebral fracture assessment, utilizing data from a computed tomography scan, retrieval and transmission of the scan data,measureme
0744TInsertion of bioprosthetic valve, open, femoral vein, including duplex ultrasound imaging guidance, when performed, including autogenous or nonautogenous patch graft (eg, polyester, ePTFE, bovine pericardium), when performed
0745TCardiac focal ablation utilizing radiation therapy for arrhythmia; noninvasive arrhythmia localization and mapping of arrhythmia site (nidus), derived from anatomical image data (eg, CT, MRI, or myocardial perfusion scan) and electrical data (eg, 12-lead
0746TCardiac focal ablation utilizing radiation therapy for arrhythmia; conversion of arrhythmia localization and mapping of arrhythmia site (nidus) into a multidimensional radiation treatment plan
0747TCardiac focal ablation utilizing radiation therapy for arrhythmia; delivery of radiation therapy, arrhythmia
0748TInjections of stem cell product into perianal perifistular soft tissue, including fistula preparation (eg, removal of setons, fistula curettage, closure of internal openings)
0749TBone strength and fracture-risk assessment using digital X-ray radiogrammetrybone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X ray data, assessment of bone s
0750TBone strength and fracture-risk assessment using digital X-ray radiogrammetrybone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X ray data, assessment of bone s
0751TDigitization of glass microscope slides for level II, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)
0752TDigitization of glass microscope slides for level III, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)
0753TDigitization of glass microscope slides for level IV, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)
0754TDigitization of glass microscope slides for level V, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)
0755TDigitization of glass microscope slide for level VI, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)
0756TDigitization of glass microscope slides for special stain, including interpretation and report, group I, for microorganisms (eg, acid fast, methenamine silver) (List separately in addition to code for primary procedure)
0757TDigitization of glass microscope slides for special stain, including interpretation and report, group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry (Li
0758TDigitization of glass microscope slides for special stain, including interpretation and report, histochemical stain on frozen tissue block (List separately in addition to code for primary procedure)
0759TDigitization of glass microscope slides for special stain, including interpretation and report, group III, for enzyme constituents (List separately in addition to code for primary procedure)
0760TDigitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, initial single antibody stain procedure (List separately in addition to code for primary procedure)
0761TDigitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, each additional single antibody stain procedure (List separately in addition to code for primary procedure)
0762TDigitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, each multiplex antibody stain procedure (List separately in addition to code for primary procedure)
0763TDigitization of glass microscope slides for morphometric analysis, tumor immunohistochemistry (eg, Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, per specimen, each single antibody stain procedure, manual (List sepa
0764TAssistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to concurrently performed electrocardiogram (List separately in addition to cod
0765TAssistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to previously performed electrocardiogram
0766TTranscutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, initial treatment, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction lo
0767TTranscutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, initial treatment, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction lo
0770TVirtual reality technology to assist therapy (List separately in addition to code for primary procedure)
0771TVirtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an in
0772TVirtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an in
0773TVirtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR pro
0774TVirtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR pro
0775TArthrodesis, sacroiliac joint, percutaneous, with image guidance, includes placement of intra-articular implant(s) (eg, bone allograft[s], synthetic device[s])
0776TTherapeutic induction of intra-brain hypothermia, including placement of a mechanical temperature-controlled cooling device to the neck over carotids and head, including monitoring (eg, vital signs and sport concussion assessment tool 5 [SCAT5]), 30 minut
0778TSurface mechanomyography (sMMG) with concurrent application of inertial measurement unit (IMU) sensors for measurement of multi-joint range of motion, posture, gait, and muscle function
0779TGastrointestinal myoelectrical activity study, stomach through colon, with interpretation and report
0780TInstillation of fecal microbiota suspension via rectal enema into lower gastrointestinal tract
0781TBronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; bilateral mainstem bronchi
0782TBronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; unilateral mainstem bronchus
0783TTranscutaneous auricular neurostimulation, set-up, calibration, and patient education on use of equipment
0790TRevision (eg, augmentation, division of tether), replacement, or removal of thoracolumbar or lumbar vertebral body tethering, including thoracoscopy, when performed
0791TMotor-cognitive, semi-immersive virtual reality-facilitated gait training, each 15 minutes (List separetely in addition to code for primary procedure)
0792TApplication of silver diamine fluoride 38% by a physician or other qualified health care professional
0793TPercutaneous transcatheter thermal ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance
0794TPatient-specific, assistive, rules-based algorithm for ranking pharmaco-oncologic treatment options based on the patient's tumor-specific cancer marker information obtained from prior molecular pathology, immunohistochemical, or other pathology results which have been previously interpreted and reported separately
0795TTranscatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or programming), when performed; complete system (i.e., right atrial and right ventricular pacemaker components)
0796TTranscatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or programming), when performed; right atrial pacemaker component (when an existing right ventricular single leadless pacemaker exists to create a dual-chamber leadless pacemaker system)
0797TTranscatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or programming), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system)
0798TTranscatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; complete system (i.e., right atrial and right ventricular pacemaker components)
0799TTranscatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; right atrial pacemaker component
0800TTranscatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system)
0801TTranscatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or programming), when performed; dual-chamber system (i.e., right atrial and right ventricular pacemaker components)
0802TTranscatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or programming), when performed; right atrial pacemaker component
0803TTranscatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or programming), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system)
0804TProgramming device evaluation (in person) with iterative adjustment of implantable device to test the function of device and to select optimal permanent programmed values, with analysis, review, and report, by a physician or other qualified health care professional, leadless pacemaker system in dual cardiac chambers
0805TTranscatheter superior and inferior vena cava prosthetic valve implantation (i.e., caval valve implantation (CAVI)); percutaneous femoral vein approach
0806TTranscatheter superior and inferior vena cava prosthetic valve implantation (i.e., caval valve implantation (CAVI)); open femoral vein approach
0807TPulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with previously acquired computed tomography (CT) images, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report
0808TPulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with computed tomography (CT) images taken for the purpose of pulmonary tissue ventilation analysis, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report
0810TSubretinal injection of a pharmacologic agent, including vitrectomy and 1 or more retinotomies
0811TRemote multi day complex uroflowmetry (eg, calibrated electronic equipment); set up and patient education on use of equipment
0812TRemote multi day complex uroflowmetry (eg, calibrated electronic equipment); device supply with automated report generation, up to 10 days
0813TEsophagogastroduodenoscopy, flexible, transoral, with volume adjustment of intragastric bariatric balloon
0814TPercutaneous injection of calcium based biodegradable osteoconductive material, proximal femur, including imaging guidance, unilateral
0815TUltrasound based radiofrequency echographic multi spectrometry (REMS), bone density study and fracture risk assessment, 1 or more sites, hips, pelvis, or spine
0816TOpen insertion or replacement of integrated neurostimulation system for bladder dysfunction including electrode(s) (eg, array or leadless), and pulse generator or receiver, including analysis, programming, and imaging guidance, when performed, posterior tibial nerve; subcutaneous
0817TOpen insertion or replacement of integrated neurostimulation system for bladder dysfunction including electrode(s) (eg, array or leadless), and pulse generator or receiver, including analysis, programming, and imaging guidance, when performed, posterior tibial nerve; subfascial
0818TRevision or removal of integrated neurostimulation system for bladder dysfunction, including analysis, programming, and imaging, when performed, posterior tibial nerve; subcutaneous
0819TRevision or removal of integrated neurostimulation system for bladder dysfunction, including analysis, programming, and imaging, when performed, posterior tibial nerve; subfascial
0820TContinuous in person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; first physician or other qualified health care professional, each hour
0821TContinuous in person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; second physician or other qualified health care professional, concurrent with first physician or other qualified health care professional, each hour (List separately in addition to code for primary procedure)
0822TContinuous in person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; clinical staff under the direction of a physician or other qualified health care professional, concurrent with first physician or other qualified health care professional, each hour (List separately in addition to code for primary procedure)
0827TDigitization of glass microscope slides for cytopathology, fluids, washings, or brushings, except cervical or vaginal; smears with interpretation (List separately in addition to code for primary procedure)
0828TDigitization of glass microscope slides for cytopathology, fluids, washings, or brushings, except cervical or vaginal; simple filter method with interpretation (List separately in addition to code for primary procedure)
0829TDigitization of glass microscope slides for cytopathology, concentration technique, smears, and interpretation (eg, Saccomanno technique) (List separately in addition to code for primary procedure)
0830TDigitization of glass microscope slides for cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal (List separately in addition to code for primary procedure)
0831TDigitization of glass microscope slides for cytopathology, cervical or vaginal (any reporting system), requiring interpretation by physician (List separately in addition to code for primary procedure)
0832TDigitization of glass microscope slides for cytopathology, smears, any other source; screening and interpretation (List separately in addition to code for primary procedure)
0833TDigitization of glass microscope slides for cytopathology, smears, any other source; preparation, screening and interpretation (List separately in addition to code for primary procedure)
0834TDigitization of glass microscope slides for cytopathology, smears, any other source; extended study involving over 5 slides and/or multiple stains (List separately in addition to code for primary procedure)
0835TDigitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site (List separately in addition to code for primary procedure)
0836TDigitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, each separate additional evaluation episode, same site (List separately in addition to code for primary procedure)
0837TDigitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; interpretation and report (List separately in addition to code for primary procedure)
0838TDigitization of glass microscope slides for consultation and report on referred slides prepared elsewhere (List separately in addition to code for primary procedure)
0839TDigitization of glass microscope slides for consultation and report on referred material requiring preparation of slides (List separately in addition to code for primary procedure)
0840TDigitization of glass microscope slides for consultation, comprehensive, with review of records and specimens, with report on referred material (List separately in addition to code for primary procedure)
0841TDigitization of glass microscope slides for pathology consultation during surgery; first tissue block, with frozen section(s), single specimen (List separately in addition to code for primary procedure)
0842TDigitization of glass microscope slides for pathology consultation during surgery; each additional tissue block with frozen section(s) (List separately in addition to code for primary procedure)
0843TDigitization of glass microscope slides for pathology consultation during surgery; cytologic examination (eg, touch preparation, squash preparation), initial site (List separately in addition to code for primary procedure)
0844TDigitization of glass microscope slides for pathology consultation during surgery; cytologic examination (eg, touch preparation, squash preparation), each additional site (List separately in addition to code for primary procedure)
0845TDigitization of glass microscope slides for immunofluorescence, per specimen; initial single antibody stain procedure (List separately in addition to code for primary procedure)
0846TDigitization of glass microscope slides for immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure)
0847TDigitization of glass microscope slides for examination and selection of retrieved archival (ie, previously diagnosed) tissue(s) for molecular analysis (eg, KRAS mutational analysis) (List separately in addition to code for primary procedure)
0848TDigitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; initial single probe stain procedure (List separately in addition to code for primary procedure)
0849TDigitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure)
0850TDigitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; each multiplex probe stain procedure (List separately in addition to code for primary procedure)
0851TDigitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; initial single probe stain procedure (List separately in addition to code for primary procedure)
0852TDigitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure)
0853TDigitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; each multiplex probe stain procedure (List separately in addition to code for primary procedure)
0854TDigitization of glass microscope slides for blood smear, peripheral, interpretation by physician with written report (List separately in addition to code for primary procedure)
0855TDigitization of glass microscope slides for bone marrow, smear interpretation (List separately in addition to code for primary procedure)
0856TDigitization of glass microscope slides for electron microscopy, diagnostic (List separately in addition to code for primary procedure)
0857TOpto acoustic imaging, breast, unilateral, including axilla when performed, real time with image documentation, augmentative analysis and report (List separately in addition to code for primary procedure)
0858TExternally applied transcranial magnetic stimulation with concomitant measurement of evoked cortical potentials with automated report
0859TNoncontact near infrared spectroscopy (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), other than for screening for peripheral arterial disease, image acquisition, interpretation, and report; each additional anatomic site (List separately in addition to code for primary procedure)
0860TNoncontact near infrared spectroscopy (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), for screening for peripheral arterial disease, including provocative maneuvers, image acquisition, interpretation, and report, one or both lower extremities
0861TRemoval of pulse generator for wireless cardiac stimulator for left ventricular pacing; both components (battery and transmitter)
0862TRelocation of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; battery component only
0863TRelocation of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; transmitter component only
0864TLow intensity extracorporeal shock wave therapy involving corpus cavernosum, low energy
0865TQuantitative magnetic resonance image (MRI) analysis of the brain with comparison to prior magnetic resonance (MR) study(ies), including lesion identification, characterization, and quantification, with brain volume(s) quantification and/or severity score, when performed, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the brain during the same session
0866TQuantitative magnetic resonance image (MRI) analysis of the brain with comparison to prior magnetic resonance (MR) study(ies), including lesion detection, characterization, and quantification, with brain volume(s) quantification and/or severity score, when performed, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the brain (List separately in addition to code for primary procedure)
0867TTransperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume greater or equal to 50 mL
0868THigh resolution gastric electrophysiology mapping with simultaneous patient symptom profiling, with interpretation and report
0869TInjection(s), bone substitute material for bone and/or soft tissue hardware fixation augmentation, including intraoperative imaging guidance, when performed
0870TImplantation of subcutaneous peritoneal ascites pump system, percutaneous, including pump pocket creation, insertion of tunneled indwelling bladder and peritoneal catheters with pump connections, including all imaging and initial programming, when performed
0871TReplacement of a subcutaneous peritoneal ascites pump, including reconnection between pump and indwelling bladder and peritoneal catheters, including initial programming and imaging, when performed
0872TReplacement of indwelling bladder and peritoneal catheters, including tunneling of catheter(s) and connection with previously implanted peritoneal ascites pump, including imaging and programming, when performed
0873TRevision of a subcutaneously implanted peritoneal ascites pump system, any component (ascites pump, associated peritoneal catheter, associated bladder catheter), including imaging and programming, when performed
0874TRemoval of a peritoneal ascites pump system, including implanted peritoneal ascites pump and indwelling bladder and peritoneal catheters
0875TProgramming of subcutaneously implanted peritoneal ascites pump system by physician or other qualified health care professional
0876TDuplex scan of hemodialysis fistula, computer aided, limited (volume flow, diameter, and depth, including only body of fistula)
0877TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained without concurrent CT examination of any structure contained in previously acquired diagnostic imaging
0878TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structure
0879TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmission
0880TAugmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and report
0881TCryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance to treatment, and removal of the oral device
0882TIntraoperative therapeutic electrical stimulation of peripheral nerve to promote nerve regeneration, including lead placement and removal, upper extremity, minimum of 10 minutes; initial nerve (List separately in addition to code for primary procedure)
0883TIntraoperative therapeutic electrical stimulation of peripheral nerve to promote nerve regeneration, including lead placement and removal, upper extremity, minimum of 10 minutes; each additional nerve (List separately in addition to code for primary procedure)
0884TEsophagoscopy, flexible, transoral, with initial transendoscopic mechanical dilation (eg, nondrug coated balloon) followed by therapeutic drug delivery by drug coated balloon catheter for esophageal stricture, including fluoroscopic guidance, when performed
0885TColonoscopy, flexible, with initial transendoscopic mechanical dilation (eg, nondrug coated balloon) followed by therapeutic drug delivery by drug coated balloon catheter for colonic stricture, including fluoroscopic guidance, when performed
0886TSigmoidoscopy, flexible, with initial transendoscopic mechanical dilation (eg, nondrug coated balloon) followed by therapeutic drug delivery by drug coated balloon catheter for colonic stricture, including fluoroscopic guidance, when performed
0887TEnd tidal control of inhaled anesthetic agents and oxygen to assist anesthesia care delivery (List separately in addition to code for primary procedure)
0888THistotripsy (ie, non thermal ablation via acoustic energy delivery) of malignant renal tissue, including imaging guidance
0889TPersonalized target development for accelerated, repetitive high dose functional connectivity MRI guided theta burst stimulation derived from a structural and resting state functional MRI, including data preparation and transmission, generation of the target, motor threshold starting location, neuronavigation files and target report, review and interpretation
0890TAccelerated, repetitive high dose functional connectivity MRI guided theta burst stimulation, including target assessment, initial motor threshold determination, neuronavigation, delivery and management, initial treatment day
0891TAccelerated, repetitive high dose functional connectivity MRI guided theta burst stimulation, including neuronavigation, delivery and management, subsequent treatment day
0892TAccelerated, repetitive high dose functional connectivity MRI guided theta burst stimulation, including neuronavigation, delivery and management, subsequent motor threshold redetermination with delivery and management, per treatment day
0893TNoninvasive assessment of blood oxygenation, gas exchange efficiency, and cardiorespiratory status, with physician or other qualified health care professional interpretation and report
0894TCannulation of the liver allograft in preparation for connection to the normothermic perfusion device and decannulation of the liver allograft following normothermic perfusion
0895TConnection of liver allograft to normothermic machine perfusion device, hemostasis control; initial 4 hours of monitoring time, including hourly physiological and laboratory assessments (eg, perfusate temperature, perfusate pH, hemodynamic parameters, bile production, bile pH, bile glucose, biliary bicarbonate, lactate levels, macroscopic assessment)
0896TConnection of liver allograft to normothermic machine perfusion device, hemostasis control; each additional hour, including physiological and laboratory assessments (eg, perfusate temperature, perfusate pH, hemodynamic parameters, bile production, bile pH, bile glucose, biliary bicarbonate, lactate levels, macroscopic assessment) (List separately in addition to code for primary procedure)
0897TNoninvasive augmentative arrhythmia analysis derived from quantitative computational cardiac arrhythmia simulations, based on selected intervals of interest from 12 lead electrocardiogram and uploaded clinical parameters, including uploading clinical parameters with interpretation and report
0898TNoninvasive prostate cancer estimation map, derived from augmentative analysis of image guided fusion biopsy and pathology, including visualization of margin volume and location, with margin determination and physician interpretation and report
0899TNoninvasive determination of absolute quantitation of myocardial blood flow (AQMBF), derived from augmentative algorithmic analysis of the dataset acquired via contrast cardiac magnetic resonance (CMR), pharmacologic stress, with interpretation and report by a physician or other qualified health care professional (List separately in addition to code for primary procedure)
0900TNoninvasive estimate of absolute quantitation of myocardial blood flow (AQMBF), derived from assistive algorithmic analysis of the dataset acquired via contrast cardiac magnetic resonance (CMR), pharmacologic stress, with interpretation and report by a physician or other qualified health care professional (List separately in addition to code for primary procedure)
33900Unilateral percutaneous pulmonary artery revascularization, initial; normal native connections
33901Bilateral percutaneous pulmonary artery revascularization, initial; normal native connections
52284Cystourethroscopy, with mechanical urethral dilation and urethral therapeutic drug delivery by drug coated balloon catheter for urethral stricture or stenosis, male, including fluoroscopy, when performed
57465Computer aided mapping of cervix uteri during colposcopy, including optical dynamic spectral imaging and algorithmic quantification of the acetowhitening effect (List separately in addition to code for primary procedure)
67516Suprachoroidal space injection of pharmacologic agent (separate procedure)
80220Hydroxychloroquine
82653Elastase, pancreatic (EL 1), fecal; quantitative
83529Interleukin 6 (IL 6)
92972Percutaneous transluminal coronary lithotripsy (List separately in addition to code for primary procedure)
95919Quantitative pupillometry with interpretation and report
A4468Exsufflation belt, includes all supplies and accessories
A4563Rectal control system for vaginal insertion, for long term use, includes pump and all supplies and accessories, any type each
A4564Pessary, disposable, any type
A6590External urinary catheters; disposable, with wicking material, for use with suction pump, per month
A6591External urinary catheter; non-disposable, for use with suction pump, per month
A7021Supplies and accessories for lung expansion airway clearance, continuous high frequency oscillation, and nebulization device (e.g., handset, nebulizer kit, biofilter)
A7023Mechanical allergen particle barrier/inhalation filter, cream, nasal, topical
A9156Oral mucoadhesive, any type (liquid, gel, paste, etc.), per 1 ml
A9268Programmer for transient, orally ingested capsule
A9269Programable, transient, orally ingested capsule, for use with external programmer, per month
A9292Prescription digital visual therapy, software-only, fda cleared, per course of treatment
A9573Injection, gadopiclenol, 1 ml
A9603SUPPLY OF THERAPEUTIC RADIOPHARMACEUTICAL, I 131 SODIUM IODIDE CAPSULE, PER MCI
A9609Fludeoxyglucose f18 up to 15 millicuries
A9610Xenon xe 129 hyperpolarized gas, diagnostic, per study dose
A9697Injection, carboxydextran-coated superparamagnetic iron oxide, per study dose
B4148Enteral feeding supply kit; elastomeric control fed, per day, includes but not limited to feeding/flushing syringe, administration set tubing, dressings, tape
E0152Walker, battery powered, wheeled, folding, adjustable or fixed height
E0183Powered pressure reducing underlay/pad, alternating, with pump, includes heavy duty
E0469Lung expansion airway clearance, continuous high frequency oscillation, and nebulization device
E0678Non pneumatic sequential compression garment, full leg
E0679Non pneumatic sequential compression garment, half leg
E0680Non pneumatic compression controller with sequential calibrated gradient pressure
E0681Non pneumatic compression controller without calibrated gradient pressure
E0682Non pneumatic sequential compression garment, full arm
E0711Upper extremity medical tubing/lines enclosure or covering device, restricts elbow range of motion
E0715Intravaginal device intended to strengthen pelvic floor muscles during kegel exercises
E0716Supplies and accessories for intravaginal device intended to strengthen pelvic floor muscles during kegel exercises
E0767Intrabuccal, systemic delivery of amplitude modulated, radiofrequency electromagnetic field device, for cancer treatment, includes all accessories
E1301Whirlpool tub, walk in, portable
E1629Tablo hemodialysis system for the billable dialysis service
E2001Suction pump, home model, portable or stationary, electric, any type, for use with external urine/or fecal management system
E2513Accessory for speech generating device, electromyographic sensor
E3000Speech volume modulation system, any type, including all components and accessories
E3200Gait modulation system, rhythmic auditory stimulation, including restricted therapy software, all components and accessories, prescription only
J0175Injection, donanemab-azbt, 2 mg
J0591Injection, deoxycholic acid, 1 mg
K1004Low frequency ultrasonic diathermy treatment device for home use
K1021Exsufflation belt, includes all supplies and accessories
K1026Mechanical allergen particle barrier/inhalation filter, cream, nasal, topical
K1027Oral device/appliance used to reduce upper airway collapsibility, without fixed mechanical hinge, custom fabricated, includes fitting and adjustment
K1030External recharging system for battery (internal) for use with implanted cardiac contractility modulation generator, replacement only
K1031Non-pneumatic compression controller without calibrated gradient pressure
K1032Non-pneumatic sequential compression garment, full leg
K1033Non-pneumatic sequential compression garment, half leg
K1037Docking station for use with oral device/appliance used to reduce upper airway collapsibility
L1653Hip orthosis, bilateral thigh cuffs with adjustable abductor spreader bar, adult size, prefabricated, off the shelf
L1821Knee orthosis, elastic with condylar pads and joints, with or without patellar control, prefabricated, off the shelf
L3161Foot, adductus positioning device, adjustable
L8720External lower extremity sensory prosthesis, cutaneous stimulation of mechanoreceptors proximal to the ankle, per leg
L8721Receptor sole for use with l8720, replacement, each
P9027Red blood cells, leukocytes reduced, oxygen/ carbon dioxide reduced, each unit
S4988Penile contracture device, manual, greater than 3 lbs traction force
S9002Intra-vaginal motion sensor system, provides biofeedback for pelvic floor muscle rehabilitation device
S9117Back school, per visit
V2525Contact lens, hydrophilic, dual focus, per lens
V2526Contact lens, hydrophilic, with blue-violet filter, per lens
Group specific policy will supersede this policy when applicable. This policy does not apply to the Wal-Mart Associates Group Health Plan participants or to the Tyson Group Health Plan participants.
CPT Codes Copyright © 2024 American Medical Association.